Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide

Chemotherapy

DRUG

Dexamethasone

Chemotherapy

DRUG

Cyclophosphamide

Chemotherapy

Trial Locations (21)

BT9 7AB

Belfast Health & Social Care Trust, Belfast

B15 2TH

University of Birmingham NHS Foundation Trust, Birmingham

B9 5SS

Birmingham Heartlands Hospital, Birmingham

BN2 5BE

Royal Sussex County Hospital, Brighton

DE13 0RB

Queens Hospital, Burton-on-Trent

CF14 4XW

University Hospital of Wales NHS Trust, Cardiff

DD1 9SY

Ninewells Hospital, Dundee

Unknown

Beatson Oncology Centre, Glasgow

LS9 7TF

St James's Hopsital, Leeds

LE1 5WW

University Hospital of Leicester NHS Trust, Leicester

EC1M 6BQ

St Bartholomew Hospital, London

NW1 2BU

University College London Hospital, London

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

W2 1NY

Imperial College Hospital, London

M13 9WL

Central Manchester Univeristy Hospital NHS Trust, Manchester

M20 4BX

The Christie Hospital, Manchester

OX3 7LE

Churchill Hospital, Oxford

S10 2RB

Sheffield Teaching Hospitals NHS FoundationTrust, Sheffield

TS19 8PE

University Hospital of North Tees, Stockton-on-Tees

WV10 0QP

New Cross Hospital, Wolverhampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Myeloma UK

OTHER

collaborator

Celgene

INDUSTRY

lead

University of Leeds

OTHER